 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: TECFIDERA (dimethyl fumarate, BG-12, Fumaderm) |
|
***************************************************** |
|
#Post#: 3000-------------------------------------------------- |
|
(Abst.) PML in Tecfidera-treated MS patients |
|
By: agate Date: August 20, 2020, 2:33 pm |
|
--------------------------------------------------------- |
|
From PubMed (August 20, 2020)--"Progressive multifocal |
|
leucoencephalopathy in dimethyl fumarate-treated multiple |
|
sclerosis patients": |
|
https://pubmed.ncbi.nlm.nih.gov/32808554/ |
|
The researchers are affiliated with the Consortium of Multiple |
|
Sclerosis Centers (CMSC) and the University of Michigan. |
|
#Post#: 3839-------------------------------------------------- |
|
PML outcomes in MS patients treated with dimethyl fumarate |
|
By: agate Date: November 14, 2022, 1:41 am |
|
--------------------------------------------------------- |
|
Some Biogen researchers have published a report on MS patients |
|
being treated with dimethyl fumarate who developed PML. |
|
From Multiple Sclerosis Journal (November 10, |
|
2022)--"Progressive multifocal leucoencephalopathy outcomes in |
|
patients with multiple sclerosis treated with dimethyl |
|
fumarate": |
|
https://journals.sagepub.com/doi/full/10.1177/20552173221132469 |
|
#Post#: 3957-------------------------------------------------- |
|
Authors' correction to the previously cited article |
|
By: agate Date: March 8, 2023, 1:35 am |
|
--------------------------------------------------------- |
|
The authors of the article in the previous post in this thread |
|
have published a correction (Multiple Sclerosis Journal, |
|
February 27, 2023): |
|
https://journals.sagepub.com/doi/full/10.1177/20552173231160312 |
|
***************************************************** |
